T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

The outcome for advanced stage hepatocellular carcinoma (HCC) remains poor, highlighting the need for novel therapies. Genetically modified mesenchymal stem cells (MSCs) are actively being explored as cancer therapeutics due to their inherent ability to migrate to tumor sites. We reasoned that MSCs...

Descripción completa

Detalles Bibliográficos
Autores principales: Szoor, Arpad, Vaidya, Abishek, Velasquez, Mireya Paulina, Mei, Zhuyong, Galvan, Daniel L., Torres, David, Gee, Adrian, Heczey, Andras, Gottschalk, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562179/
https://www.ncbi.nlm.nih.gov/pubmed/28856237
http://dx.doi.org/10.1016/j.omto.2017.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562179/
https://www.ncbi.nlm.nih.gov/pubmed/28856237
http://dx.doi.org/10.1016/j.omto.2017.07.002

Ejemplares similares